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Abstract: The pathophysiological link between type 2 diabetes mellitus (T2DM) and 
Alzheimer’s disease (AD) has been suggested in several reports. Few findings suggest that 
T2DM has strong link in the development process of AD, and the complete mechanism is yet 
to be revealed. Formation of amyloid plaques (APs) and neurofibrillary tangles (NFTs) are 
two central hallmarks in the AD. APs are the dense composites of β-amyloid protein (Aβ) 
which accumulates around the nerve cells. Moreover, NFTs are the twisted fibers containing 
hyperphosphorylated tau proteins present in certain residues of Aβ that build up inside the 
brain cells. Certain factors contribute to the aetiogenesis of AD by regulating insulin signaling 
pathway in the brain and accelerating the formation of neurotoxic Aβ and NFTs via various 
mechanisms, including GSK3β, JNK, CamKII, CDK5, CK1, MARK4, PLK2, Syk, DYRK1A, 
PPP, and P70S6K. Progression to AD could be influenced by insulin signaling pathway that is 
affected due to T2DM. Interestingly, NFTs and APs lead to the impairment of several crucial 
cascades, such as synaptogenesis, neurotrophy, and apoptosis, which are regulated by insulin, 
cholesterol, and glucose metabolism. The investigation of the molecular cascades through 
insulin functions in brain contributes to probe and perceive progressions of diabetes to AD. 
This review elaborates the molecular insights that would help to further understand the potential 
mechanisms linking T2DM and AD.
Keywords: Alzheimer’s disease, type 2 diabetes mellitus, insulin deficiency, insulin signaling 
pathway, cholesterol
Introduction
Many reports suggest a strong pathophysiological links between type 2 diabetes 
mellitus (T2DM) and Alzheimer’s disease (AD). Prevalence of T2DM and its asso-
ciated complications leads to AD that increases with time in the aging population, 
with profound oxidative stress (OS) potentially relating the molecular mechanisms 
involved in T2DM–AD linkage.1,2 Insulin action in the brain stimulates the modulation 
of numerous molecular cascades, such as cholesterol metabolism, energy expenditure, 
glucose homeostasis, feeding behavior, synaptogenesis, neurotrophy, neurotransmitters, 
cognition, memory, inflammation, apoptosis, and reproduction.3 In addition, insulin 
regulates the metabolism of peripheral β-amyloid peptide (Aβ) and hyperphosphory-
lated tau protein. In AD, the extracellular accumulation of Aβ plaques, intracellular 
aggregation of hyperphosphorylated tau protein in neurofibrillary tangles (NFTs), and 
neuronal loss occur in the cortex and hippocampus.4,5 Hence, the disruption of insulin 
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functions in diabetic conditions, like hyperinsulinemia and 
hyperglycemia, interrupts insulin signaling involved in the 
clearance of Aβ plaques and NFTs pathology. This leads 
to the accelerated formation of neurotoxic Aβ and NFTs 
via various mechanisms, including GSK3β, JNK, CamKII, 
CDK5, CK1, MARK4, PLK2, Syk, DYRK1A, PPP, and 
P70S6K contributing to the aetiogenesis of AD.1,2,6 In this 
review, we discuss the roles of aberrant brain insulin sig-
naling in T2DM leading to AD and the mechanisms in the 
deposition of Aβ and NFTs and their therapeutic potential in 
restoring the brain pathways that might contribute to T2DM 
and AD treatment.
Insulin hormone linking type 2 diabetes 
and AD
The excessive insulin finds way into the brain and inter-
rupts the biochemistry.7–9 One of the possible mechanisms 
could be the modification of insulin signaling involved in 
a variety of neuronal functions of brain, such as abnormal 
protein O-GlcNAcylation, alteration of mitochondria, OS, 
glucose metabolism, and cholesterol, as well as amyloid 
plaques (APs) formation, changed Aβ metabolism, and 
tau hyperphosphorylation protein deposition.1,8,10 Reduced 
insulin plasma levels in T2DM can impair this signaling 
pathway forming two core neuropathological hallmarks 
of AD, ie, NFTs and Aβ plaque, which leads to impaired 
memory and cognitive dysfunction.11,12 The progression of 
diabetes to AD and their molecular cascades involved in the 
function of insulin are discussed below (Table 1).
Insulin and brain
Regulation of carbohydrate and fat metabolism is medi-
ated by insulin hormone via stimulating the absorption of 
glucose from the blood to fat tissue and skeletal muscles. 
Disturbance in insulin in the periphery system may cause 
diabetic mellitus (DM), but in the brain develop certain 
neurodegenerative states like mild cognitive impairment 
(MCI) and AD. However, brain itself can also synthesize 
some portion of insulin and crosses the blood–brain barrier 
(BBB) through a saturable transporter within the central 
nervous system (CNS) that affects feeding and cognition 
through CNS mechanisms that are independent of glucose 
utilization.3,8,13,14 Studies on the mechanisms of insulin pro-
duction and secretion in the CNS show similarities between 
beta cells and neurons, remarkably in the context of ATP-
sensitive K+ (KATP) channel depolarization.15,16 Increased 
number of insulin receptors (IRs) during cell differentiation 
in the brain recommends important role of IR signaling 
in neuronal proliferation during development, maturation, 
regeneration of axons, and neurite outgrowth in developing 
neurons projections as they grow (Figure 1).8,17,18
Cholesterol metabolism
Cholesterol which is metabolized in the brain plays a crucial 
role in cell membrane, independent from peripheral tissues 
featuring BBB, where it plays important membrane func-
tion, acts as an antioxidant, and serves as the raw material 
to produce steroidal progesterone which modulates neuroen-
docrine functions that alter physiology and behavior in the 
CNS. Interestingly, in adipose tissue breakdown of fat is 
inhibited by insulin which is responsible for the intracellular 
lipase inhibition that demands triglycerides to hydrolyze 
and release fatty acids. Moreover, insulin stimulates entry 
of glucose into adipocytes to synthesize glycerol within the 
cells, thereby enhancing the rate of glucose translocation 
across the cell membrane, muscles, and in adipose tissue. 
Then, apolipoprotein E (ApoE)-cholesterol particle is pro-
cessed to free the cholesterol in the lysosomes and is then 
transported to the membrane. ApoE isoform ε4 is the most 
common risk factor for AD that correlates with escalation of 
Aβ clearance and accumulation in the brain during AD.19–22 
Thus, insulin alteration in diabetes can interrupt brain choles-
terol metabolism leading to metabolic dysfunction, thereby 
causing neurological disorders (Figure 2).23
Glucose uptake
Uptake of glucose, the main fuel in body, varies among the 
tissues depending on the tissue metabolic needs and glucose 
availability. The glucose transporter (GLUT) protein iso-
forms are involved in facilitating the translocation of glucose 
in which the prominent isoforms are GLUT1-4. Glucose 
uptake is stimulated by the movement of GLUT4 transporters 
from the intracellular membrane into the plasma membrane 
which demands GLUT4-containing vesicles to facilitate the 
process.24 In the kidney, glucose uptake is accomplished by 
the secondary active transport mechanism through GLUT2 
transporter, linked to Na+/K+ pump reliant on the sodium 
gradient generated by NaKATPase. Malfunctioning of 
GLUT4 protein in the hippocampus affects the biochemical 
reactions and cognitive flexibility offered by hippocampal 
neurons, thus developing depression and lowering the cogni-
tive function which in turn increases the risk of Alzheimer 
development (Figure 3).25–27
GLUT function can be regulated by insulin-like growth 
factor (IGF) family. IGF is very close to the natural human 
growth hormone and consists of three ligands (insulin, IGF-1, 
and IGF-2), six IRs (IRα [fetal], IRβ [adult], IGF-1 receptor 
[IGF-1R], IGF-2R, hybrid IGF-1R/IRα, hybrid IGF-1R/IRβ), 
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Table 1 Effect of insulin on brain: decrease of insulin via various pathways could lead to the effects on the brain which in turn contributes 
to Alzheimer’s disease
Region Effect of insulin Progress of insulin action Ref
Peripheral 
tissues, 
hippocampus
Regulation of glucose homeostasis 
through relationship between 
brain insulin receptors and 
neurotransmitters
1. Induced neuronal norepinephrine inhibition and serotonin reuptake 
stimulation
2. increased food intake in the insulin resistance to facilitate peripheral 
elevation of free fatty acids and release of proinflammatory cytokines
3. Reduced O-GlcNAcylation of tau in brain hypometabolism and 
increased tau phosphorylation and NFTs formation in AD
4. impaired mitochondrial function and thiamine-dependent processes in 
the cerebral glucose hypometabolism of AD
5. Diminished insulin efficiency to block the glucose formation
6. induced opening of ATP-sensitive K+ channels leading to cell 
hyperpolarization
8, 191–193
Hypothalamus Production of liver glucose stimulus 
of the acute nucleus
1. Stimulus transmission to the vagal motor nucleus nerve to produce 
appropriate response in the liver
2. Decreased insulin inhibitory effect on the glucose hepatic production
194–198
Neurons and 
glial cells
Induction of forebrain neuron growth 
and differentiation and NGF to 
stimulate neuritis formation
Associated to the cerebral insulin actions, including cell growth
Hippocampus 
(CA1)
induction of PSD-95 expression, a 
dendritic scaffolding protein
Activated Pi3K/mTOR pathway 199
Hippocampus 
(CA1)
Synaptogenesis, synaptic function 
modulation, and regulation of dendritic 
spine formation and excitatory synapse 
development
1. Upregulated Tau protein
2. Stabilized tubulin mRNA and increased protein levels
200, 201
Human CNS 
and NSC
Proliferation and differentiation of 
multipotent neural stem cells and 
prevention of apoptosis, Aβ toxicity, 
oxidative stress, and ischemia
1. Prevented apoptosis through PI3K pathway, but via MAPK pathway
2. Protected cells against Aβ-induced cell apoptosis
202, 203
extrasynaptic 
space
induction of GABA and glutamate 
accumulation
1. elevated neuronal antioxidants such as uric acid, glutathione, and 
vitamins C and E
2. Altered glucose metabolism and decreased lactic acidosis
204, 205
Hippocampus Anti-ischemic effect Stimulated Na+/K+ ATP pump to reduce extracellular K+ and intracellular 
Na+ to change neuronal firing rate and its metabolic demands
Rat 
hippocampus
Anti-ischemic effect 1. induced Akt and JNK1/2 cross-talk
2. Reversed induction of JNK1/2 phosphorylation, Bcl-2 expression, and 
caspase-3 cleavage
8
Hypothalamus Alteration of intracellular ion 
concentrations
1. Stimulated Na+/K+ ATP pump
2. Increased intracellular Ca2+ concentration triggering neuropeptide release
70
Hypothalamus Modulation and stimulation of 
aminoacid uptakes, neurotransmitter 
receptor density and synthesis
1. Reduced the increase of striatal dopamine receptor numbers and CSF 
serotonin levels
2. Downregulated α2-adrenergic receptors in the hypothalamic neurons
206, 207
Hypothalamus 
synapses
Modulation of glutamatergic 
neurotransmission at the synapses and 
induction of LTD process by reduction 
of AMPA receptor levels in the 
postsynaptic membrane
1. Phosphorylation of the hormone receptor, Pi3-kinase activation
2. Induced GluR2 subunit phosphorylation in the AMPA receptors to 
produce endocytosis and decrease of postsynaptic excitatory ability
208, 209
CNS induction of GABA receptor effects on 
learn and memory processes
1. Stimulated GABA receptor translocation to plasma membrane
2. Abolished by PI3K inhibitor
3. increased expression of functional GABA receptors on the 
postsynaptic and dendritic membranes of CNS
210–212
CSF induction of tyrosine, tryptophan 
azidothymidine, and leptin 
transportation from blood to the brain
Induced P-gp expression involved in the BBB integrity and protects brain 
against numerous exogenous toxins
213
Brain 
microvessels
induction of neurochemical 
modifications in the brain microvessels
1. Inhibited alkaline phosphatase activity
2. increased expression and activity of glutamate–cysteine ligase catalytic 
subunit by inducing antioxidant response element-4
8, 214, 215
Choroid 
plexus
Inhibition of serotonin receptor 
5-HT2C receptor activity
Modulated GPCR by tyrosine kinase receptor–MAP kinase pathway
Abbreviations: Aβ, β-amyloid protein; AD, Alzheimer’s disease; BBB, blood–brain barrier; CNS, central nervous system; CSF, cerebro spinal fluid; GABA, gamma-amino 
butyric acid; LTD, long term depression; MAPK, mitogen-activated protein kinases; mTOR, mammalian target of rapamycin; NGF, nerve growth factor; NSC, neural stem 
cells; Pi3K, phosphoinositide-3-kinase.
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Figure 1 Regulation of carbohydrate and fat metabolism, mediated by insulin hormone in the brain, on central and peripheral functions.
Notes: Regulation of carbohydrate and fat metabolism is mediated by insulin through increasing the transport of glucose from the blood to fat tissue and skeletal muscles. 
Disturbance in the insulin levels in the periphery system leads to diabetes, but in the brain develops certain neurodegenerative states such as AD.
Abbreviations: AD, Alzheimer disease; ARC, arcu ate nucleus.
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and up to seven IGF-binding proteins (IGFBP1-7).28,29 IGF-1 
and insulin can control the neuronal excitability, metabo-
lism, and survival through insulin/IGF-1 signaling pathway. 
Abnormality and disruption in the activity of these pathways 
trigger the continuous dwindle of neurons in AD brain.30,31 
Few evidences on the brain of AD patients showed deficit 
ratio of insulin and resistance in IGF-1, suggesting that 
AD might be a brain-type diabetes or diabetes type 3.32,33 
Altered neuronal IGF-1 function seems to be an impor-
tant aspect of the overall synaptic and neuronal pathology 
induced by Aβ protein precursor (AβPP)-Aβ clearance 
in the apoE4 carriers. Hence, both hyperinsulinemia and 
hyperglycemia can increase the neuritic plaque formation 
and progress in AD.30,34
energy expenditure
The amount of energy which is consumed for the perfor-
mance of physical activities, such as inhalation and exha-
lation, blood circulation, breakdown of food particles, or 
physical movement, is known as energy expenditure. This 
energy is obtained by the electrochemical gradient generated 
by the electron transport chain (ETC) which drives ATP 
synthesis via ATP synthase. The ATP production capacity 
and/or efficiency is performed via mitochondrial dynamics 
in beta cells.35,36
Leptin as an adipocytokine which is produced in the 
peripheral system as well as in the brain possesses key role 
in phenomena such as food intake, obesity, glucose homeo-
stasis, and energy expenditure. It is proved that both leptin 
expression levels and signaling pathways could be con-
nected to the pathophysiology of many neurodegenerative 
diseases, such as AD. It is illuminated that leptin receptors 
are highly expressed in the hippocampus involved with 
learning and memory, and are found critically affected in 
AD patients. In vivo and in vitro studies suggest that leptin 
supplementation could decrease both Aβ production and tau 
phosphorylation which contribute to the development process 
and pathogenesis of AD.37 Insulin secretion occurs in blood 
stream based on the availability of free fatty acid, amino 
acid, and beta cell measures glucose through mitochondrial 
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Figure 2 Crucial role of cholesterol in membrane.
Notes: Cholesterol is imported through receptor-mediated endocytosis of lipoproteins and through lysosomes and transported to the cell membrane. Thus, it causes the 
interruption on brain cholesterol metabolism, thereby leading to neurological disorders.
Abbreviation: Pi3K, phosphoinositide-3-kinase.
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respiration and nutrient oxidation accordingly. The main 
stimulator of insulin secretion signal is elevation of cytosolic 
ATP/ADP ratio or high glucose oxidation, mitochondrial 
ATP synthesis, and low ATP demand in the beta cells.38,39 
Permanent excess nutrient or continuous exposure to fat in 
T2DM damages mitochondria or decreases its function in the 
beta cell through reduced antioxidant activity and sustained 
overproduction of reactive oxygen species (ROS), indepen-
dent of changes in mitochondrial ATP synthesis.40 Besides, 
NF-kβ, TNF-α, and IL-6 as acute inflammatory cytokines 
lead to negative energy balance and promote energy expen-
diture and increase ROS.41,42
It is shown that abnormal production of AT-derived 
proteins contributes to the pathogenesis of insulin resistance 
and metabolic syndrome such as T2DM.9,43 The inflammatory 
cytokines elevation, energy expenditure, and insulin defi-
ciency result in high glucose expenditure and accumulation 
of β-amyloid peptide as a hallmark of AD.8,9,28
Role of leptin in glucose homeostasis
A balance between the insulin and glucagon maintains blood 
glucose levels or glucose homeostasis. Insulin exerts its 
pleiotropic effects through binding to the insulin receptor 
substrate (IRS) proteins which mediate regulation of glucose 
transport, protein metabolism, and control of cell growth 
and survival. IRS proteins connect insulin receptor activa-
tion to essential downstream kinase cascades, such as the 
phosphoinositide-3-kinase (PI3K) or mitogen-activated 
protein kinases (MAPK) pathways. Decreased IRS-1 contrib-
utes to reduction of glucokinase and increases blood glucose 
levels in diabetes.44–46
As we know, hypothalamus regulates leptin signaling 
that has a role in food intake and energy homeostasis in 
mammals which results in the downregulation of orexio-
genic peptides, such as neuropeptide Y (NPY) and agouti-
related peptide (AgRP), and in reverse, it can increase the 
expression of anorexiogenic peptides, such as α-MSH, 
which promotes energy expenditure in either adipose or 
skeletal muscle tissue. It is indicated that leptin-mediated 
ObRb receptors are expressed in vast density in the arcu-
ate nucleus (ARC), dorsomedial nucleus (DMH), and the 
ventromedial nucleus (VMH) of the hypothalamus. In the 
ARC, obRb is rarely expressed in two different neuronal 
cell types of the hippocampus (CA1 and CA3 regions) and 
the dentate gyrus,47 which express both NPY and AgRP, and 
proopiomelanocortin (POMC) is mainly expressed.48,49 Also, 
leptin increases synaptogenesis and aids in memory forma-
tion in the hippocampus and is pretended to be a cognitive 
promoter.50 Similarly, it was shown to elevate neurogenesis 
in the dentate gyrus in rodents.51 Leptin also plays a vital 
role in hippocampal neuronal survival via activating the 
PI3K/Akt/mammalian target of rapamycin (mTOR), as 
well as the AMP-activated protein kinase (AMPK)/SIRT1, 
JAK2/STAT3, ERK pathway signal transduction pathways 
through binding to its long-form receptor obRb.52 Leptin 
upregulates the expression of some potent endogenous anti-
oxidant enzymes involved in apoptosis, such as manganese 
superoxide dismutase and the anti-apoptotic protein Bcl-xL 
in the hippocampus.52
Leptin can modulate Aβ production and metabolism. 
Interestingly, chronic peripheral leptin administration in 
Tg2576 mice reduced tau phosphorylation explicitly at 
residues Ser202, Ser396, and Ser404 in retinoic acid. Such 
reduction is suggested to be mediated via AMPK, Akt, and 
p38 pathways.53,54 All these evidences could illuminate the 
role of leptin in T2DM and highlight AD linkage. Moreover, 
epidemiological studies have also found depleted leptin 
levels in the pathogenesis of AD. In a study by Narita et al, 
it was found that higher leptin levels positively correlate with 
higher hippocampal volumes.55 It should be noted that all the 
leptin-induced signaling pathways link to phosphorylation 
of glycogen synthase GSK3β and decrease in hyperphos-
phorylation of tau.56 It is interesting that the low circulating 
leptin levels, in turn, could potentially contribute to cognitive 
decline and worsen the pathology, leading to a downward 
spiral of further weight loss and progression of AD.57 The 
presence of amyloid plaques, NFTs, and neurodegenera-
tion in the hypothalamus of human AD brains suggest that 
Aβ-mediated suppression of leptin-responsive cells in the 
hypothalamus is extremely possible.58,59 Hence, leptin may 
possess a bidirectional role in the dysfunction of leptin sig-
naling that exacerbates AD pathology.
In addition, insulin activates PKB (or Akt) which is a 
serine/threonine kinase, composed of various members, 
including PKBα (Akt1) and PKBβ (Akt2). Only PKBα 
drives islet and β-cell proliferation. Interestingly, PKBα-
deficient mice also revealed normal insulin-stimulated 
disposal of blood glucose.60,61
TNF-α is a key cytokine that influences intermediary 
glucose metabolism which compromises IR/IRS-1 signaling 
independently of transcriptional regulation. This effect 
is mediated by minimum of seven serine kinases, which 
include c-JUN-NH
2
-terminal kinase (JNK), Akt/PKB, and 
IKK. Tyrosine phosphorylation of IRS-1 and IRS-2 serine 
at 307 residues is an essential factor to actively downstream 
effector pathways impairment in the insulin homeostasis. 
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Insulin homeostasis impairment affects glucoregulatory 
mechanisms characterized by altered glucose tolerance and 
causes insulin resistance leading to escalation of Aβ peptide, 
APP, NFTs neurotoxicity, and tau phosphorylation associ-
ated with AD.8,61,62
Feeding behavior
Controlling the body mass by maintaining food consumption 
underlies a twisted flow. Excess of food intake contributes to 
the onset and progression of the metabolic syndrome. Some 
hormones such as insulin, glucagon-like peptide 1 (GLP-1), 
and leptin are involved in the regulation of food uptake and 
energy consumption.63–66 Insulin with leptin exerts their acute 
effect by altering cells’ function and nutritional behavior via 
PI3K pathway. PI3K increases α-MSH release and decreases 
NPY release which induces depolarization of AgRP neurons 
and increases food intake. GLP-1 also regulates glucose 
homeostasis and reduces food intake. Food intake and 
the anorexic brain-gut peptide GLP-1 activate amygdala 
dopamine signaling through D2 receptor which is necessary 
and sufficient to alter the feeding behavior.67–69
Hypothalamic AMPK regulates food intake as well as 
body weight through altering the expression of NPY, AgRP, 
POMC, and CART in the ARC nucleus. Unlike feeding, 
fasting increases hypothalamic AMPK activity. In the hypo-
thalamus, minimum of two mechanisms exert impact on the 
anorexigenic effects on AMPK inhibition which results in 
the activation of acetyl-CoA carboxylase (ACC) and mam-
malian target of rapamycin (mTOR), and the phosphorylation 
of p70S6 kinase (p70S6K).68–71 In T2DM, increased mTOR 
and p70S6 kinase expressions elevate production of leptin 
which has direct effects on food intake. Feeding behavior 
dysfunction in T2DM modulates brain functionality leading 
to neurodegeneration process such as AD through overpro-
duction of APP, Aβ 1–42, and thereby accumulations of Aβ, 
and also contributes to NFTs production.2,72
Synaptogenesis feeding behavior
Synaptogenesis is a multi-step process of synapse for-
mation which is promoted by IGF-1 and IGF-2 through 
several pathways during all the major phases of neurode-
velopment. The activation of protein kinase C (PKC) also 
regulates synaptogenesis through phosphorylation, binding 
to signaling lipids, and translocation from the cytosol to the 
membrane.17,29,73–75 Phosphorylation of PKC at the first step 
is essential for its activation and formation of its catalytically 
active competent conformation. PI3K activation by insulin 
also induces synaptogenesis and controls the expression of 
synaptic markers in addition to their accumulation in the 
nerve cells. PI3K, accompanied with the existing elements 
of the InR signaling pathway, controls cellular magnitude, 
growth and multiplication, and creation of synapses in 
between the neurons. PI3K and B/Akt protein kinase regulate 
the development of synapses as well as their preservation. 
PI3K acts via its binding to synapsin, actin filaments, and 
high phosphoinositide levels that are linked to the cAMP 
pathway and cAMP response.60,76 The sites of expression of 
IRSp53 in the synapses are located on the granular layer of 
the cerebellum and hippocampal neurons, which suggests 
that these molecules are components of insulin-dependent 
signaling pathway at the postsynaptic apparatus. IRSp53 is 
a key factor in cytoskeleton which is phosphorylated upon 
stimulation with insulin and involved in neurite outgrowth 
and neurodegenerative disorders.8,77 Insulin stimulates 
translation, but not the transcription, of postsynaptic den-
sity PSD-95 in the hippocampal CA1 neurons, through 
the PI3K–Akt–mTOR pathway, an important intracellular 
signaling pathway in regulating the cell cycle.74,78 There is 
a linkage between the phosphorylation of IGF1-induced 
Akt and release as well as the translocation of GLUT4 from 
intracellular pools to nerve process membranes in the normal 
developing brain. High glutamate levels phosphorylate the 
Ser (307) residue in the IRS-1 protein which develops less 
reactivity and induces IGF-I via activation of pathway associ-
ated with protein kinase A (PKA) and PKC. This action arises 
due to a reciprocal activity between IGF-1 and nerve growth 
factor (NGF) in the peripheral nerves, where the PI3K/Akt/
GSK3 pathway underlies the impact raised from the coop-
eration of both agents on axonal growth. Insulin signaling 
pathways activate PKC and its substrates, many of which are 
vital components of synaptogenesis, cognition and neuronal 
repair, differentiation, growth, and apoptosis.79
Insulin also activates MAPK pathway through tyrosine 
phosphorylation of certain prototypical signaling adaptors 
such as Shc/Grb2, SOS/Grb2, and Gab-1/Shp2. Diabetes 
declines the activity of PI3K/AKT/mTOR in the enteric 
neurons, which impairs retrograde NGF transport in the 
vagus nerve. Activation of PI3-phosphatase decreases 
cellular contents of lipid products by PI3K. Any defects in 
the intracellular PI3K translocation or phosphatase activa-
tion may modify Akt/PKB activity.74,78,80 Synaptogenesis 
and synaptic remodeling increase Aβ oligomers which can 
directly produce neuronal insulin resistance and directly bind 
to PKC and inactivates it. GSK-3β phosphorylates multiple 
sites of tau protein in the intact cells. Aberrant hyperphos-
phorylated tau protein is a critical feature in AD pathogenesis 
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that signifies a close molecular relationship between diabetes 
and AD.74,80,81
Neurotrophy
Neurotrophy or nerve damage is strongly regulated by insulin 
which is essential for neuronal development and survival via 
IGF-1 and ROS signaling pathways. IGF-1 pathway coor-
dinates growth, proliferation, differentiation, development, 
metabolism, and glucose homeostasis. The graft of IGF-1 and 
the related receptor trigger the phosphorylation of essential 
adaptor proteins together with Shc and IRSs, which leads to 
the activation of two prosurvival signaling pathways.75,82,83 
Phosphorylation of IRS-1 or IRS-2 stimulates PI3K–PDK1–
AKT signaling pathway, whereas phosphorylation of Shc 
induces RAS, RAF, and ERK/MAPK signaling pathway 
which leads to regulation of neurotrophy. Moreover, phos-
phorylation of threonine 308 via PDK1 or phosphorylation of 
serine 473 via mTORC2 results in the activity of AKT; this 
activation increases the life span of cells through abundant 
mechanisms, like deterrence of apoptosis and giving rise 
to prosurvival gene expression. Decreased levels of serum 
IGF-I in DM patients with sensory and autonomic neuropathy 
compared with nonneuropathic DM or nondiabetic controls 
and IGF-I and IGF-II lead to sympathetic neuroaxonal 
dystrophy. IGF-1 blocks amyloid toxicity by increasing 
survival signaling through PI3–AKT and ERK which accu-
mulate high levels of Aβ from overexpressing APP. The Aβ 
oligomers elevate pro-inflammatory cytokines in the brain 
that mimic the trophic factor/insulin resistance as observed 
in AD brain.18,30,71,75,84
Apoptosis
Several studies suggest the protective role of insulin against 
apoptosis through various signaling pathways that suppress the 
excessive accumulation of ROS within the cells.85 The insulin/
IGF/Akt is one of these pathways in promoting β-cell survival. 
However, ER stress–induced apoptosis is mediated at least in 
part by signaling through the phosphatidylinositol 3-kinase/Akt/
GSK3β pathway. Moreover, presence of advanced glycation 
end products (AGEs) and advanced lipoxidation end products 
(ALE) that merely resulted from a long-term accumulation of 
modified protein can be considered as a stress. Chronic hyper-
glycemia-induced OS such as nitric oxide (NO) plays a central 
role in the formation of AGEs in DM.86,87 G-protein-adenylyl 
cyclase signaling, diacylglycerol (DAG)/PKC pathway, 
and calcium movement play a vital role in diabetes-induced 
galactooligosaccharide (GOS). Normalization of mitochondrial 
superoxide production blocked AGEs overproduction, PKC 
activation, and increased glucose flux through the aldose 
reductase pathway and NF-kB activation.88,89
Impaired immune system in diabetes is almost affiliated 
with the reduction of antioxidant activity and antioxidant 
enzymes manifestation as well as eccentric performance 
or abnormal enzyme activities. Among the diversity of the 
existing antioxidant enzymes, SOD, GPx, and CAT reflect 
greater impact on the regulation of ROS formation and entire 
antioxidant content available in a certain tissue as well as 
in DM.90–92 NADPH oxidase and dysfunction of mitochon-
drial respiratory chain (MRC) are also a major source of 
ROS in diabetes. Thus, blocking the overexpression and 
activation of this enzyme and subsequent ROS production 
together with its ROS scavenging property reduce OS in 
diabetes. Mitochondrial-derived superoxide anion is com-
mon in complications with diabetes. Overexpression of 
manganese-dependent superoxide dismutase (Mn-SOD), 
which is the major scavenger of mitochondrial superoxide 
anion and mitochondrial DNA damage in T2DM, prevents 
high glucose-induced OS and cell apoptosis. OS-related 
pathways interconnect AD and T2DM. It is a well-known 
connection of Aβ protein and hyperphosphorylated tau with 
glucose metabolic intermediates and IRs. Insulin transporters 
cause this interconnection in the AD brain, Aβ accumulates 
in the plaques, and receptor for AGE mediates Aβ 1–42-
induced perturbations of APP and NFTs neurotoxicity 
(Figure 4).18,87,89,93
Neurotransmitters
Endogenous chemical messengers that enable transmission 
of signals from one neuron to the target neuron, muscle 
cell, or gland cell stimulating insulin and glucagon are 
demarcated as neurotransmitters. Glutamate is one of the 
most abundant neurotransmitters in the brain; an excess 
of glutamate overstimulates brain cells, which results in 
neurological inflammation and cell death. A high glutamate 
concentration triggers insulin release to lower glucose levels 
which in turn increases glutamate. Another neurotransmitter, 
gamma-amino butyric acid (GABA) in the CNS, prevents 
nerve transmission in the brain and has a calming nervous 
activity. Heavy secretion of insulin results in a protracted 
secretion of GABA, glutamate, aspartate, and taurine through 
the number of GABA
A
 receptors. Moreover, insulin therapy 
could be considered as an efficient therapy to bridle the toxic 
activity of neurotransmitters to preserve neurons. Therefore, 
there is a close linkage between GABAergic signaling system 
and various aspects of AD pathology, including tau hyper-
phosphorylation, Aβ toxicity, and apoE4 effect. Low levels 
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Figure 4 The protective role of insulin against apoptosis through various signaling pathways to suppress the excessive accumulation of ROS within the cells results in early 
diabetic retinopathy.
Abbreviations: ROS, reactive oxygen species; AGe, advanced glycation end product; PeDF, pigment epithelium-derived factor.
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of GABA and glutamate cause significant limitation in the 
activities of synapses and synaptic transmission of neurons in 
the temporal cortex of AD patients, and activation of GABA
A
 
receptors induces tau hyperphosphorylation.18,94–96
Promoting glycogen synthesis
Synthesis of glycogen from glucose in skeletal muscle 
is regulated via the activity of certain hormones such as 
insulin. Muscle and liver uptake the available glucose upon 
stimulation by insulin hormone and leads to the activation of 
glycogen synthase (GS) through dephosphorylation of three 
specific serine residues, collectively termed sites 3.97–99
GS kinase (GSK)-3 is principally responsible for phospho-
rylation of sites 3, whereas phosphatase (PP)-1, a glycogen-
bound form of protein, dephosphorylates these sites.100 
However, defeat in tracing the fall in quantity of cAMP 
localization in muscles is associated with a secondary glyco-
gen synthase kinase which is not influenced by cyclic nucle-
otides. Immediate effect of insulin is to redirect synthesized 
glucose-6-phosphate to glycogen without affecting the rate 
of gluconeogenesis which requires hepatic Akt2-dependent 
redirection of glucose-6-phosphate to glycogen independently 
of GSK3α and GSK3β phosphorylation. Downstream defects 
at the level of glycogen synthase kinase (GSK)-3 or impaired 
regulation of the GSK3 target site of GS (site 3a/b/c and 4) 
which leads to abnormal phosphorylation in activation of 
GS and dysregulation of CaMKII seems as a major cause 
of insulin resistance phenomenon. In AD brain, increased 
activities of Akt, PKA, and GSK3α, and β and Aβ-induced 
GSK3β phosphorylation increase tau phosphorylation which 
leads to mitochondrial dysfunction.99–102
Cognition and memory
Controlling the transmission of ions through neuroreceptors 
located on the membrane is activated by neurotransmitters 
and synaptic transmission which influence the cognitive 
function in the presence of insulin.77 Suppression of Wnt or 
PI3-kinase signaling ruin the synaptic connections between 
neurons which is known as long-term potentiation (LTP) and 
results in the less synaptic strength which affects the process 
of learning and memory function. GSK3β at high expression 
level suppresses LTP impact, thus providing lesser spatial 
learning.103,104 GSK3 also phosphorylates and inhibits cAMP-
responsive element-binding protein, a universal modulator 
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of memory.105 Moreover, GSK3 promotes actin and tubulin 
assembly, processes required for synaptic reorganization 
during memory formation. PI3K/Akt/GSK-3β is another 
pathway to impair the ability of insulin in activation of 
glucose disposal and glycogen synthase in T2DM. Overex-
pression of GSK3 induces a series of pathological changes, 
most of which are hallmarks of AD and T2DM incurring 
severe pathology, such as cognitive decline. Adiponectin 
is an important target for AD by induction of Aβ and Tau 
phosphorylation in hippocampus and extrahypothalamic 
region. GSK3β together with GSK3α causes AD by induc-
ing tau hyperphosphorylation to form NFTs through PI3K/
Akt/GSK-3β signaling pathway.103,106–108
Inflammation
Insulin suppresses the pro-inflammatory proteins such as 
JNK, IKKβ/NF-kB, AP1, CAM1, PSD95, and MCP1 which 
downregulate the inflammatory response. Inflammation 
together with insulin resistance is increased by expression 
of several pro-inflammatory cytokines such as interleukin 
(IL)-1, IL-6, and tumor necrosis factor (TNF)-α. In contrast, 
IKKβ acts selectively against the physiological substrates 
and the IkB protein inhibitors of NF-kB. Phosphorylation 
by IKKβ targets IkBα to degrade proteasome that liberates 
NF-kB for translocation from cytoplasm into nucleus to pro-
mote expression of numerous target genes and consequently 
induce insulin resistance.42,62,109–111
PI3K–Akt–mTOR signaling pathway facilitates the syn-
thesis of PSD-95 protein via insulin induction in Dendron’s 
and hippocampal area. PSD-95, a 95-kDa scaffolding 
protein of PSD, is degraded by IL-1β. T2DM enhances pro-
inflammatory factors in the brain cells such as microglia and 
astrocytes that contribute and provoke AD. Inflammatory 
agents like toxicants and pollutants when accumulated in 
higher proportion lead to cellular stress, amyloid precursor 
protein (APP), and rise in genesis state, thereby stimulating 
amyloid-β–42 (Aβ–42) peptide production.78,112
Role of insulin resistance and tau protein 
in AD
Insulin resistance, impaired glucose tolerance, and forma-
tion of insoluble protein aggregates, as well as the loss of 
neurons and synapses, extend risk factors in the develop-
ment process of AD, but evidence for this assertion is not 
consistent. Impaired insulin signaling certainly does not 
preclude evidence from having a deficit effects on cognition 
independent of its role in AD pathology, such as diminished 
learning, memory, problem solving, and mental flexibility. 
Mechanisms of T2DM progression to AD by insulin are 
classified into two main categories: NFTs and Aβ formation. 
Various experimental paradigms suggest that Aβ and tau have 
been found to exert synergistic modes of toxicity, while the 
effect of insulin on the brain is complex and not confined to 
Aβ production (Figure 5).2,9,18,113,114 Tau protein plays a wider 
role in cellular shape, motility, and signal transduction in 
AD. The C-terminal of this protein is probably responsible 
for tubulin-binding and the acidic N-terminal region interacts 
with other cytoskeletal elements. The proline-rich middle 
region contains the target sites of many kinases. Moreover, 
R1–R4 are four repeat domains called microtubule-binding 
domains (MBDs) and each of them repeats and conserves 
consensus motif KXGS, which can be phosphorylated at 
serine.115,116
Insulin can modulate phosphorylation of tau protein 
which are MBD molecules involved in microtubule assembly 
and stabilization. Dysfunction of insulin can cause tau hyper-
phosphorylation through two different mechanisms at 
specific amino acids including Ser and Thr: glucose/energy 
metabolism and temperature independent.117,118 Out of 85 
phosphorylatable residues in tau protein, 28 sites are exclu-
sively phosphorylated in AD brains (Table 2). Reduced 
insulin plasma levels in T2DM can impair this signaling 
pathway resulting in tau hyperphosphorylation and disinte-
gration of microtubules and thereby formation of NFTs.115 
Most promising candidate kinases for tau phosphorylation 
which are responsible to provoke AD and T2DM are listed 
in Table 2. The details and the functions of each kinase are 
as follows:
GSK3β
It was shown that H
2
O
2
 increases GSK-3β activity in human 
embryonic kidney 293/Tau cells which leads to tau hyper-
phosphorylation at Ser396, Ser404, and Thr231. GSK3β is 
involved in the formation of both Aβ deposits and NFTs, 
two pathological features of AD. The Aβ promotes GSK-3β 
activity in the neuronal cells which is at Thr231 residue, 
but it enhances phosphorylation at the S9, S68, T69, T71, 
T175, and Ser396/404 sites which decreases tau–microtubule 
interactions and the pathologic fibril formation, thereby 
reducing tau binding to microtubules.119–122
c-JUN-NH2-terminal kinase
The JNK is a subfamily of the MAPK that binds and phospho-
rylate c-Jun on Ser-63 and Ser-73 within its transcriptional 
activation domain. The β2-adrenergic receptor (β2AR)–
PKA–JNK pathway phosphorylates tau protein at Ser-214, 
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Figure 5 Glucose tolerance and DM are the syndromes in the elderly and there is evidence in supporting a link between insulin dysfunction and AD.
Abbreviations: AD, Alzheimer disease; DM, diabetic mellitus; ROS, reactive oxygen species.
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Ser-262, Thr231, and Thr-181, which are utilized by Aβ 
signals in the primary neurons of prefrontal cortex (PFC) in 
mouse brain.123 Knocked-out β2AR mice showed an extreme 
decrease of phosphorylation of presenilin 1 (PS1) and APP 
associated to the Aβ-induced tau pathology in AD. Aβ also 
induces the clusterin/p53/Dkk1/wnt–PCP–JNK pathway, 
which drives the upregulation of several genes that mediate 
development of AD-like neuropathologies; these studies are 
in agreement with the animal experiments.124
JNK plays a critical role in regulation of insulin signaling, 
inflammatory response, apoptosis, and caspase-3 activity in 
diabetes and increases the expression of IL-6, IL-8, monocyte 
chemotactic protein-1, and tumor necrosis factor-α 35 in 
AD pathology.8,125,126
CamKII
Calcium-/calmodulin-dependent protein kinase type II is one 
of the abundant Ca2+-regulated protein kinases in the brain; 
these kinases are expressed primarily in neurons. CaMKII 
is regulated by Ca2+-/CaM-induced autophosphorylation at 
multiple sites such as Thr 286/287.127 The tau phosphoryla-
tion is upregulated at Ser214, Ser262, Ser131, Thr212, and 
Thr135 by CaMKII kinase in frontal cortex and hippocampus, 
and is found in PHF-tau of AD brains and T2DM which 
leads to the inactivation of protein phosphatases (PP).118,128 
Obviation of synapses results in depleting the memory 
function in preliminary stage of AD which is expected to be 
induced via Aβ oligomers by CaMKII. O-GlcNAc modifica-
tion by CaMKII at Ser 279 activates CaMKII autonomously, 
creating molecular memory even after Ca2+ concentration 
declines in T2DM.129 Furthermore, it was shown that the 
activation of CaMKII directly inhibits AGEs formation 
significantly and reverses D-ribose-induced tau hyperphos-
phorylation which links T2DM to AD.115,128
CDK5
Cdk5 belongs to the Cdk family which is expressed in the 
CNS and other tissues. It regulates several cell processes 
such as neuronal migration, actin, and microtubule dynam-
ics. Cdk5 acts through PP1 and regulates several proteins 
such as inhibitor-1 (I-1) and I-2. P25 is a neurotoxic activa-
tor of cdk5 which triggers tau phosphorylation and NFTs 
formation in AD pathophysiology.130 Moreover, p35 is a 
neuronal-specific protein that is nonhomologous to cyclins, 
and is responsible for the identification and activation of 
Cdk5 in association with Cdk5R1 or Cdk5R2. Interest-
ingly, the study on gene-targeted therapy opens up the clue 
with potential role of p35/Cdk5 kinase in the migration 
process of neurons as well as in the development stage 
of mammalian cortex.131 Expression of Cdk5 and its co-
activator p35 is upregulated in the presence of high glucose 
concentration and strong bounding with Cdk5 kinase is 
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Table 2 Progression of diabetes to AD, the molecular cascade involving the function of insulin in the brain: the enzymes which are 
activated in diabetes type 2 could phosphorylate the specific Tau residues leading to ADs
Kinase Residue(s) Alzheimer’s linked phosphorylation Ref
GSK3β S68, T69, T71, 
T175, S235
Leads to Thr231 phosphorylation and consequent pathologic fibril formation, inhibits 
the ability of tau to stabilize microtubules and cell death
119–122
GSK3β, Dyrk1a, JNK, 
MAKR, p38 (MAPK)
T181, S63, S73 Leads to early events in NFT formation and deregulating tau–microtubule interactions 
and indicative of the presence of pretangle tau
121, 216
PLK2 S129 •	 Inhibits the α-syn-induced tau mass to form intracellular neurofibrillary tangle-like 
aggregates
•	 Upon investigation of phosphorylation spots, it was found that numerous factors 
including glycogen synthase kinase 3 beta or MAP/microtubule affinity-regulating 
kinase 2 may be associated with this effect
153, 217, 218
Syk/Fyn Y18 •	 Leads to congregation of microtubules and their solidity along with its involvement in 
the formation and preservation of neuronal polarity
•	 Hypophosphorylation of Y 18 has the role in neurodegeneration
•	 The reciprocal action between direct Syk and α-syn was proven by a dual-hybrid 
system approach and confocal microscopy
•	 To be involved in neurons cell-signaling pathway
154, 219
GSK-3 S191 •	 Leads to abolishing the microtubule-stabilizing effect which is observed in 
tau-transfected cells
•	 In immature neurons, S191 phosphorylation may favor the microtubule dynamics 
which is probably required for neurite growth
•	 The aberrant hyperphosphorylation of tau in AD may shift the balance toward 
excessive microtubule
•	 Leads to defective axonal transport of organelles and impaired retrograde axonal 
transport of neurotrophic factors as well as to alterations in neurite morphology
220–222
Syk/TTK1 Y197
Cdk5, PKA, GSK-3, 
Dyrk1a, JNK, MARK, 
p38, CK1
T175, T181, 
S184, S195, S198, 
S199, S202, S235, 
S356, S396, S400, 
S404
•	 Prevent pathologic tau fibril formation and develop pathologic tau fibrils, and thus 
indicating a potential therapeutic avenue for amyotrophic lateral sclerosis with 
cognitive impairment
•	 Leads to physiological role of microtubule dynamics regulator, whereas another 
set (overlapping or not with the previous one) leads to aggregation into PHFs, 
degradation, and/or toxic function
•	 Leads to detachment of tau from microtubules
•	 Leads to the formation of a linkage between p-p70S6K (T421/S424) and S262 or 
S396/404, by facilitating site-specific phosphorylation on regulatory (T389) and 
catalytic (T229) domains
•	 A raise in the function of 70S6K might be possible, which in turn may phosphorylate 
tau at T212, S214, and S262 sites
•	 Leads to attachment with some proteins such as PP-1, actin, PP-2A, phospholipase C, 
α-synuclein, and glycogen synthase kinase-3β which is related to AD
121, 122, 161, 
190, 223, 224
Cdk5, CK1, PKA, 
GSK-3, PKB/Akt
S214 •	 Leads to suppress tau-dependent microtubule polymerization and inhibit axonal 
elongation in neurons
•	 Leads to reduce its ability to bind to microtubules
•	 To have some effects on microtubule association on tubulin, the tau-interacting site 
is located at the carboxyl terminal end, which is highly acidic and detaches from 
microtubules
•	 Leads to reductions of the tau–microtubule interaction in vitro
•	 Leads to suppress microtubule assembly, and may be a key factor in the observed 
detachment of tau from microtubules during mitosis
223, 225, 226
GSK3β, Cdk5 S202, T205 •	 Leads to microtubule dynamics regulatory
•	 Leads to detachment of tau from microtubule
227–229
Cdk5, PKA, CK1, 
GSK-3, PKB/Akt
T212, T214, 
T262
•	 Level of (70-kDa p70 S6 kinase) p-p70S6K (T421/S424) is only significantly correlated 
with p-tau at T212, S262, and S214, but not at T212/S214, in AD brains. These 
suggested that p70S6K might contribute to tau-related pathologies in AD brains
•	 Leads to compromise its binding ability to microtubules
•	 Phosphorylation of protein tau at the S262 site perhaps leads to the suppression of 
microtubule clustering and their stabilization. However, T212 site did not express 
a significant potency to assemble microtubules; prephosphorylation at this site has 
been shown to enhance S214 phosphorylation
119, 121, 123, 
154, 216, 228, 
230
(Continued)
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maintained. In contrast, transforming growth factor beta 
receptor I (Tgfbr1) inhibitors downregulate the expression 
of Cdk5 and p35 kinase activity. Similarly, early growth 
response protein 1 (Egr-1) has a capacity to highly express 
in the presence of glucose by mediating TGF-β1-ERK1/2 
pathway and its inhibition by siRNA downregulates p35 
and Cdk5 scenario.132 Moreover, protein–protein interac-
tions regulate the activity of Cdk5 with the intervention 
of regulatory and target molecules having substantial 
association with nestin in approaching p35, demonstrating 
streamlined flow and continuation of Cdk5/p35 activity. 
The truncated form of p35 molecule, p25, acquires and 
gathers in higher amount in the brain of AD patients’ 
neurons. This increases Cdk5 kinase activity by repel-
ling the degradation of p35 to p25 and binding of p25 to 
Cdk5 reflecting its cellular location and alters its substrate 
specificity. Hyperphosphorylation of tau molecules by 
p25/Cdk5 complex reduces its ability to associate with 
microtubules, thereby inducing cytoskeletal disruption, 
morphological degeneration, and apoptosis. Therefore, 
various findings support the idea of indicating p35 cleavage 
and accumulation of p25 involvement in the pathogen-
esis of cytoskeletal abnormalities and neuronal death.133 
Cdk5 is also expressed in adipocytes to phosphorylate 
Table 2 (Continued)
Kinase Residue(s) Alzheimer’s linked phosphorylation Ref
•	 Ps262 leads to microtubule-binding repeat domain which can be detached from 
the microtubules and may thus be protective in preventing tau aggregation into 
AD-like PHFs
•	 Perhaps, the phosphorylation of tau at T212 and S214 sites result in the 
neutralization of the fundamental charges, followed by the neutralization of inhibitory 
effect of S262 phosphorylation that causes tau to self-assemble into filaments
•	 Leads to the disconnection of microtubules and blockage of PHF formation in 
degenerating neurons in AD
•	 Leads to reduce its ability to bind to microtubules
•	 Leads to detach from microtubules
•	 Leads to strongly decrease the tau–microtubule interaction in vitro
•	 Leads to inhibition of microtubule gathering and might induce detachment of tau 
protein from microtubules during mitosis
GSK-3, Cdk5, PKA
Dyrk1a, JNK, MAPK
T231 •	 Prevents pathologic tau fibril formation, regardless of Thr175 state and develop 
pathologic tau fibrils
•	 Leads to fibril formation, indicating a potential therapeutic avenue for amyotrophic 
lateral sclerosis with cognitive impairment
•	 Leads to less binding potency microtubules via the activity of Ras–MAPK pathway
•	 Pin1 interacts only with phosphorylated T231; this connection evolves a 
conformational alteration resulting in the attachment of tau protein to microtubules
121, 122, 216, 
228, 231, 232
GSK-3, Cdk5, PKA, 
Dyrk1a, JNK, MARK
S262, S393, S324, 
S356
•	 Prevents the binding to microtubules 115 and aggregate into PHFs
•	 Leads to destabilizing microtubule assembly; functions and localizations of other 
subcellular structures such as mitochondria and lysosomes could be altered
•	 Leads to exert itself toxic effect on microtubule binding, and can lead to the 
breakdown of the microtubule network and cell degeneration
•	 Appears to play a major part in regulating its ability to interact with microtubules
113, 119, 216, 
223, 233
CK1, GSK-3, PKA, 
CAMKII
S409, S412, S413, •	 Disrupts microtubule affinity-regulating kinase (MARK2)/PAR-1b and protein kinase 
A (PKA), both of which are involved in the regulation of microtubule stability and 
neurite outgrowth
119, 216, 222, 
228, 229, 234
CAMKII, PKA, MARK S416 •	 Serine 416 is strongly phosphorylated at early developmental stages in rat brain; 
therefore, CaM kinase II is involved in the accumulation of tau in neuronal soma in 
AD brain
222, 229, 235
MAPK, GSK3β, PKA, 
Cdk5, Dyrk1a, JNK, 
p38, TTKi
S422 •	 S422 on caspase cleavage of tau may partly explain the delayed appearance of Tau-
C3-positive NFT; the eventual appearance of Tau-C3 reactive tangles makes it clear 
that phosphorylation takes place at S422
•	 Prevents segregation during the lower activity of caspase, but may be overwhelmed 
as caspase activity levels increase
•	 Leads to defensive operation resulting in the suppression of tau protein cleavage. 
Lead to abbreviate the transition path in vivo leading to fibril formation or develop 
stability of filaments in AD
216, 228, 229, 
236–239
Abbreviations: AD, Alzheimer disease; NFT, neurofibrillary tangles; JNK, c-JUN-NH2-terminal kinase; PKA, protein kinase A; MAPK, mitogen-activated protein kinases; 
PHFs, paired helical filaments; PP, protein phosphatases.
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proliferator-activated receptor gamma (PPARγ) which 
leads to metabolic syndromes such as T2DM.134,135 High 
glucose levels induce the expression of p35 and Cdk5 
through TGF–β1–ERK1/2–Egr-1 pathway leading to create 
high ROS.132 ROS also induces tau hyperphosphorylation 
and neuroinflammation in AD and T2DM via increasing 
proinflammatory mediators and the expression of TNF-α, 
IL-1β, and IL-6, and apoptosis.136,137
CK1
CK1, a ubiquitous serine/threonine-selective protein kinase, 
is mainly expressed in the neurons. CK1 is involved in the 
tau hyperphosphorylation and Aβ production which has 
been evidenced by the increased levels of CK1ε protein or 
mRNA leading to elevated phosphorylation of many sites of 
tau protein such as S262, S356, and S214, involved in AD 
and T2DM.121,138
PKA and PKB
PKA and PKB, the two members of phosphoinositide-
dependent PK, play a central role in cellular signaling by the 
process of phosphorylation. PKA phosphorylates many sites 
of tau such as Ser262 and Ser409 to increase cAMP levels as 
a prime for CK1 and GSK-3, whereas PKB phosphorylates 
this protein at Thr212 and Ser214 which promotes tau attach-
ment to the 14-3-3 as studied in the in vitro model. Phospho-
rylation of tau at S241 by both PKA and PKB is associated 
with organization of microtubule cytoskeleton and formation 
of NFTs in AD.139–141 These two kinases increase glucose 
uptake and inotropic effects in adipocytes and pancreatic 
cells, and glucotoxicity, as well as promote proliferation in 
the beta cells which are involved in progression of T2DM.142 
Blocking IP modulation of hepatic gluconeogenesis through 
PKA/CREB and PI3K-γ/PKC-ζ/TRB3/AKT pathway can 
also contribute to the T2DM progression.143
P38
P38 enzymatic activity in the MAPK reacts to the stress 
induction, in addition to apoptosis, leading to hyperglycemia 
that induces OS. This phenomenon, p38 MAPK pathway 
activation via tau protein phosphorylation, initiates devel-
opment of AD and T2DM.144,145 Many studies have shown 
that activated p38 is exclusively localized to the NFTs and 
coimmunoprecipitated with PHF-tau in the hippocampal and 
cortical brain regions of AD brain.146,147
MARK4
MARK4, also known as Par-1d/MarkL1, is a member of the 
AMPK, which is implicated in the regulation of glucose and 
energy homeostasis. Phosphorylation of the microtubule by 
this kinase causes its detachment from the microtubules. 
MARK selectively phosphorylates existing S262 and S356 
emerged in every MBD and other proteins that influence 
microtubules to facilitate the formation of cell processes.148,149 
It was reported that MARK4 deficiency mitigated insulin 
resistance enhancing insulin-stimulated AKT phosphoryla-
tion in major metabolic tissues.150
PLK2
Upregulation of PLK2 (SNK) is mediated by the increased 
α-syn phosphorylation at S129 site which elevates pre-form 
of α-syn fibrils and with Aβ leading to tau hyperphospho-
rylation and reduction of tau binding to microtubules to 
promote the formation of NFTs-like aggregates in AD.151,152 
Tau phosphorylation leads to aggregation of this protein 
by co-expressing glycogen synthase and kinase 3 beta or 
MAP/microtubule affinity-regulating kinase 2 involved in 
the progression of T2DM.153
Syk
Syk, a tyrosine kinase of tau protein at tyrosine 18 and α-syn, 
probably could influence the function and physiology of 
neurons in the brain.154 The tau in the detergent-resistant 
membranes is a tyrosine phosphorylated form which harbors 
lipid rafts. This form of tau protein is expected to facilitate a 
neurotoxic reactance towards Aβ. Syk can phosphorylate tau 
protein at Y18, Y197, and Y394 sites, respectively. Although 
other src family kinases may phosphorylate tau in the brain, 
PHF-tau is phosphorylated at tyrosine 394 and Fyn is the 
strongest candidate for tyrosine phosphorylation.117,155,156
DYRK1A
This kinase plays an important role in the signaling path-
ways which regulate cell proliferation and probably brain 
development. Dyrk1A mediates phosphorylation at the 
Thr356 and T181 residues of GSK3β that can inhibit its 
activity. Since DYRK1A pathway involves in the regulation 
of β cell mass and carbohydrate metabolism, defect in this 
protein could lead to T2DM.157,158
PPP
PPP group includes serine/threonine PP 1, 2A, 2B, and 5. 
Activity of PP2A in the normal brain is more than in AD 
brain (71% vs 50%), but activity of PP1 and PP5 in normal 
is less than in AD brain (11% and 10% vs 20% and 20%, 
respectively). PP1, PP2A, PP2B, and PP5 dephosphorylate 
tau protein at various sites, implicated in the stability and 
function regulation of microtubule. PP1 and PP2A are asso-
ciated in a state where tau protein is hyperphosphorylated 
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significantly than the tau protein in normal brain. PP5 at 
a higher expression level affects phosphorylation spot by 
removing the phosphate groups. Thus, it promotes neurons 
preservation vs apoptosis induced by Aβ.159,160
P70S6K
Protein, p70S6K, accompanied with Ser-Thr kinase, phos-
phorylates the ribosomal S6 subunit, the fundamental sequel 
in cell cycle control, growth, and differentiation leading to 
tau accumulation by translation and upregulating the expres-
sion. At protein level, the epitope T421/S424 of p-p70S6K 
is associated with tau phosphorylation. These epitopes phos-
phorylate tau at S214, S262, and T212 sites in AD brain, and 
inhibit recombinant tau assembly in vitro. Activated p70S6K 
in NFT-bearing neurons might be caused by the aberrant 
regulation of P13K and MAPK pathways, as well as the 
reduced activity of PP2A in AD brain. Deposition of Aβ in 
the AD brain also contributes to activation of p70S6K and 
consequential formation of tau-associated pathologies in AD 
brain, P70s6k plays a critical role in the early development 
process of T2DM as well. IRs mediate PI3K and p70S6K 
activation during insulin stimulation.161–163
Aggregation and degradation 
of hyperphosphorylated Tau
Approximately 90% of APP can be processed by 
nonamyloidogenic pathway and the remaining is processed 
by amyloidogenic pathway.
Nonamyloidogenic pathway
In nonamyloidogenic or nonplaque-forming pathway, 
a transmembrane protein known as APP is segregated via 
α-secretase enzyme leading to the formation of carboxy termi-
nus fragment α (CTFα) and soluble APP fragment α (sAPPα). 
Later, γ-secretase segregates CTFα, which ends up with the 
induction of APP intracellular cytoplasmic domain (AICD) 
and p3 peptide. Probably, the sAPPα, which is considered as 
neuroprotective factor, is associated with the establishment of 
synapses within the neurons, neurite outgrowth, and neuronal 
survival. AICD may be involved in nuclear signaling via 
transcriptional regulation as well as axonal transport through 
its ability to associate with various proteins.164,165
Amyloidogenic pathway
In the amyloidogenic or plaque-forming pathway, APP and 
β-secretase are interposed within the endosome with an acidic 
environment, inducing β-secretase to segregate APP protein, 
following the formation of CTFβ and soluble APP fragment 
β (sAPPβ). Consequently, CTFβ is cleaved by γ-secretase 
enzyme to form AICD and Aβ fragments. Later, sAPPβ 
together with Aβ liberates into the extracellular environment 
where Aβ fragments accumulate to form plaques.
Aβ aggregation and plaque formation
Aβ peptide chain contains 38 (Aβ
38
), 40 (Aβ
40
), or 42 (Aβ
42
) 
amino acids. Aβ
42
 is chemically stickier compared with the 
other peptides. All three genetic mutations that cause early-
onset AD change the role of gamma secretase, leading to an 
increased production of Aβ
42
.166,167 Aβ peptides aggregate 
into oligomers to organize fibrils with the formation of AP. 
Aβ plaques block signaling pathways and cells connection, 
which can be lethal to cells. Further, it can cause NTFs forma-
tion and Aβ is thought to cause oxidative damage to the cells. 
Along with the development of NFTs, low levels of insulin 
can increase the Aβ levels and forms AP in the brain. The 
Aβ peptide acts as monomers, dimers, or multimers on cell 
membranes and binds to its receptors on neuronal and glial 
cells at the nanomolar concentration to interfere with neu-
rotransmission and memory before the AP builds up.5,168,169
Insulin–amyloid plaque–neurofibrillary 
tangles
Insulin regulates peripheral Aβ and tau metabolism which 
influences the Aβ release in the brain through regulating APP 
metabolism to modulate the balance between Aβ anabolism 
and catabolism.170 Lack of insulin or its action may link T2DM 
to AD by modification of Aβ production and degradation. 
Defect in the insulin-dependent pathways may increase the 
activation of GSK3 associated with the risk of AD. T2DM also 
modifies mitochondrial antioxidant defense system and assists 
brain weakness in the presence of Aβ toxicity.
A link between the involvement of insulin-degrading 
enzyme (IDE) in hyperinsulinemia and AD is closely 
related to dysfunction in the metabolic and neurological 
pathways.171,172 IDE is a thiol zinc-metallo-endopeptidase that 
cleaves small proteins such as insulin, Aβ, glucagon, calci-
tonin, and amylin which leads to the formation of β-pleated 
sheet-rich amyloid fibrils under certain conditions; levels of 
insulin together with Aβ in the brain are regulated by IDE. 
Interestingly, the hypofunction of this enzyme triggers the 
formation of AD and T2DM.
Role of antidiabetic drugs on Alzheimer’s 
disease
The incidence of MCI more often seen in T2DM patients 
may develop to AD. Therefore, improvement in cognition 
with antidiabetic drugs could be a strategy rather than mere 
glycemic control. Interestingly, these drugs could benefit 
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AD patients associated with T2DM and it remains to be 
determined whether the potential is due to glucose lowering 
or the neuroprotective effects. However, further research 
is warranted to investigate their links between cognitive 
impairment and AD, and their safety measure is important 
too when considered in the management setting.
We highlight the potential of antidiabetic drugs with 
experimental and clinical observation through numerous 
studies that would be of interest to the researchers in devel-
oping strategies and linking in-depth mechanisms.
Biguanides
Metformin is an oral hypoglycemic drug under biguanide 
class used in the treatment of diabetes. In experimental 
studies, metformin showed neuroprotective role by pre-
venting etoposide-induced apoptotic cell death in primary 
neurons and improved oxygen-glucose in neuronal injury. 
McNeilly, in 2013, demonstrated that in high fat-diet-induced 
animals, metformin attenuated the insulin resistance and 
weight gain, but had no effect on performance in either mas-
sive transfusion protocol (MTP) or no MTP (nMTP) tasks. 
In addition, metformin has shown to prevent the appearance 
of molecular and pathological characteristics of AD in neuro-
blastoma cell line model of insulin resistance. Interestingly, 
in diabetic rat model, metformin has revealed the reduction 
of cell proliferation and neuroblast differentiation in hip-
pocampal dentate gyrus.173–176
Ng et al investigated the effect of metformin on the risk 
of cognitive impairment and its possible modulation by 
apolipoprotein E (ApoE) ε4 gene polymorphism. Metformin 
did not show any significant interactive role with ApoE 
ε4 and depression. Interestingly, among individuals with 
diabetes, long-term treatment (.6 years) reduced the risk 
of cognitive decline.
On other hand, the clinical studies on metformin show that 
the subjects aged 50 years and older significantly decreased 
the risk of dementia when compared with non-medication 
group after adjustment for cerebrovascular disease.177 
In contrast, a case–control study displayed that long-term 
users of metformin were at greater risk of developing AD.178 
Similarly, a study which included AD and cognitively intact 
patients showed worse cognitive performance in metformin 
users compared with those who were taking metformin 
and calcium together.179 Altogether, these studies raise the 
possible confounding effects of metformin in the manage-
ment process of AD/neurological function, and therefore 
needs further understanding through molecular biomarkers 
approaches in clinical studies.
Sulfonylurea
Sulfonylureas such as glyburide and glipizide inhibit mTOR 
activation in the experimental model, as we know aber-
rant PI3K/mTOR activation is commonly experienced in 
diabetes and AD.180 Glyburide has been shown to inhibit 
inflammasomes responsible for the elevation of proinflam-
matory cytokines resulting in neuroinflammation associated 
with AD.181
In clinical studies, sulfonylureas do not alter the risk 
of developing AD in a long-term population-based case–
control study.178 However, combination of metformin and 
sulfonylureas in a prospective cohort study over the period 
of 8 years reduced the risk of dementia by 35%, but their 
efficacy in preventing or improving memory and cognition 
needs to be determined.177
Thiazolidinediones
Thiazolidinediones such as rosiglitazone and pioglitazone 
might have role in reducing the risk of neurodegeneration.182 
Rosiglitazone has shown protective effects in experimental 
models against neuronal insulin resistance induced by beta 
amyloid oligomers.183 On the other hand, pioglitazone 
showed improved cognitive performance in a rat model of 
memory impairment.184
In randomized controlled trial (RCT), rosiglitazone 
preserved memory function in patients with early AD and 
amnestic MCI but beta amyloid continued to be stable in plas-
ma.172 Another small randomized double-blind trial on rosigl-
itazone demonstrated improvement in cognitive function in 
mild-to-moderate AD patients who were not carriers of the 
ApoE ε4 allele.185 In multicenter randomized concept clinical 
trial, rosiglitazone ameliorated impairment of brain glucose 
metabolism in mild-to-moderate AD subjects, but did not 
show evidence of slowing clinical progression.186 Another 
RCT on pioglitazone significantly decreased AD assessment 
scale (ADAS) score in AD/MCI subjects.187 In contrast, 
Phase III trial on rosiglitazone monotherapy failed to show 
a benefit on cognitive outcomes in mild-to-moderate AD.188 
Similarly, another population–based case–control study did 
not change the risk of developing AD.178
Glucagon-like peptide 1
Another study on GLP-1 receptor agonists, liraglutide and 
lixisenatide, reduced the hippocampal burden and improved 
spatial memory in AD transgenic mice.189 Liraglutide ame-
liorated tau hyperphosphorylation and restored brain insulin 
sensitivity in type 2 diabetic rats.190 Thus, liraglutide dimin-
ishes neurodegenerative developments in AD.
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Overall, preclinical and clinical studies support the effi-
cacy of antidiabetic drugs in cognitive enhancement; some 
studies have failed to confirm reports of improved cognition 
in patients with T2DM even after good glycemic control. 
However, more clinical studies on antidiabetic drugs in agree-
ment with preclinical approaches would enhance the chance 
of correlating MCI/AD for better therapeutic strategy and 
thereby increase the quality of life in AD patients.
Conclusion
This review extracted valuable outcomes from the studies 
that described the underlying common mechanisms between 
T2DM and AD, and the molecular determinants which could 
have significant therapeutic potential in treatment of T2DM- 
and/or AD-related damages. It was concluded that those 
patients who develop T2DM often suffer from dementia which 
might be AD. These patients could also suffer from hypergly-
cemia, hypercholesterolemia, and insulin signaling dysfunc-
tions which are common features to T2DM. In addition, some 
antidiabetic drugs could have beneficial effects against some 
AD hallmarks, such as tau hyperphosphorylation, Aβ plaque 
formation, and apolipoprotein particularly ApoE4. Therefore, 
cardiometabolic signaling needs appropriate crosstalk to 
understand the mechanism and linkage with neuroinflamma-
tion process in the neurodegenerative disorders.
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